[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 8555 Introduced in House (IH)]

<DOC>






116th CONGRESS
  2d Session
                                H. R. 8555

   To direct the Secretary of Health and Human Services to submit to 
  Congress a weekly report on COVID-19 vaccine distribution, and for 
                            other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                            October 9, 2020

  Ms. Craig introduced the following bill; which was referred to the 
                    Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
   To direct the Secretary of Health and Human Services to submit to 
  Congress a weekly report on COVID-19 vaccine distribution, and for 
                            other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Vaccine Fairness Act of 2020''.

SEC. 2. COVID-19 VACCINE DISTRIBUTION REPORT.

    (a) In General.--Not later than 7 days after the date on which the 
Federal Government begins distributing COVID-19 vaccines for 
administration to the public, and every 7 days thereafter, the 
Secretary of Health and Human Services (in this section referred to as 
the ``Secretary''), in consultation with the Secretary of Defense, 
shall submit to Congress a report on the effectiveness of efforts 
relating to the distribution of COVID-19 vaccines to the public.
    (b) Contents of Report.--Each report submitted under subsection (a) 
shall include, with respect to the 7-day period preceding the date on 
which such report is submitted, the following:
            (1) The number of doses of COVID-19 vaccines distributed 
        for administration to the public.
            (2) A description of any substantial purchase of COVID-19 
        vaccines by a Federal Government agency or private 
        organization.
            (3) The number of doses of COVID-19 vaccines that were 
        distributed to State or local health departments.
            (4) A description of the progress made in distributing 
        COVID-19 vaccines to the following:
                    (A) High-risk and other priority groups, 
                including--
                            (i) racial and ethnic minorities;
                            (ii) individuals who are pregnant or 
                        breastfeeding;
                            (iii) individuals with disabilities;
                            (iv) homeless individuals;
                            (v) newly resettled refugees; and
                            (vi) individuals in rural communities.
                    (B) High-risk facilities, including--
                            (i) long-term care facilities;
                            (ii) group homes; and
                            (iii) jails and prisons.
            (5) A description of any deviations from Federal 
        distribution plans, including issues relating to the following:
                    (A) Sites administering large numbers of COVID-19 
                vaccines, such as pharmacy chain stores, schools, and 
                primary health care providers.
                    (B) Tracking procedures for COVID-19 vaccines, 
                particularly in areas of greatest need.
                    (C) Outreach to health care providers and the 
                public about the availability, benefits, safety, 
                contraindications, and costs of receiving COVID-19 
                vaccines.
                    (D) Outreach to health care providers regarding the 
                responsibilities of such providers to track vaccine 
                administration and monitor adverse events.
                    (E) Uniform record keeping relating to the 
                administration of COVID-19 vaccines (including Federal 
                support for State and local immunization information 
                systems).
                    (F) Overuse or gaps in treatment.
    (c) Briefings.--On each date on which the Secretary submits to 
Congress a report under subsection (a), the Secretary shall be 
available to brief Congress on the contents of such report.
    (d) Termination.--This section shall cease to have effect on the 
date that is 18 months after the date on which the initial report is 
submitted to Congress under subsection (a).
    (e) State Defined.--In this section, the term ``State'' means each 
of the several States, the District of Columbia, each commonwealth, 
territory, or possession of the United States, and each federally 
recognized Indian Tribe.
                                 <all>